These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38356330)

  • 1. Discovery of Effective Dual PROTAC Degraders for Neurodegenerative Disease-Associated Aggregates.
    Zhu W; Zhang W; Chen J; Tong Y; Xu F; Pang J
    J Med Chem; 2024 Mar; 67(5):3448-3466. PubMed ID: 38356330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted degradation of ⍺-synuclein aggregates in Parkinson's disease using the AUTOTAC technology.
    Lee J; Sung KW; Bae EJ; Yoon D; Kim D; Lee JS; Park DH; Park DY; Mun SR; Kwon SC; Kim HY; Min JO; Lee SJ; Suh YH; Kwon YT
    Mol Neurodegener; 2023 Jun; 18(1):41. PubMed ID: 37355598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, Synthesis and Biological Evaluation of α-Synuclein Proteolysis-Targeting Chimeras.
    Wen T; Chen J; Zhang W; Pang J
    Molecules; 2023 May; 28(11):. PubMed ID: 37298935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural alkaloid harmine promotes degradation of alpha-synuclein via PKA-mediated ubiquitin-proteasome system activation.
    Cai CZ; Zhou HF; Yuan NN; Wu MY; Lee SM; Ren JY; Su HX; Lu JJ; Chen XP; Li M; Tan JQ; Lu JH
    Phytomedicine; 2019 Aug; 61():152842. PubMed ID: 31048127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. α-mangostin derivative 4e as a PDE4 inhibitor promote proteasomal degradation of alpha-synuclein in Parkinson's disease models through PKA activation.
    Chen JY; Zhu Q; Cai CZ; Luo HB; Lu JH
    Phytomedicine; 2022 Jul; 101():154125. PubMed ID: 35525236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lycorine, a natural alkaloid, promotes the degradation of alpha-synuclein via PKA-mediated UPS activation in transgenic Parkinson's disease models.
    Zhu Q; Zhuang XX; Chen JY; Yuan NN; Chen Y; Cai CZ; Tan JQ; Su HX; Lu JH
    Phytomedicine; 2021 Jul; 87():153578. PubMed ID: 34038839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breaking Bad Proteins-Discovery Approaches and the Road to Clinic for Degraders.
    Bouvier C; Lawrence R; Cavallo F; Xolalpa W; Jordan A; Hjerpe R; Rodriguez MS
    Cells; 2024 Mar; 13(7):. PubMed ID: 38607017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of Small-Molecule Degraders for Alpha-Synuclein Aggregates.
    Tong Y; Zhu W; Chen J; Wen T; Xu F; Pang J
    J Med Chem; 2023 Jun; 66(12):7926-7942. PubMed ID: 37267712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Advances in PROTACs for Drug Targeted Protein Research.
    Yao T; Xiao H; Wang H; Xu X
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective degradation of EGFR
    Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
    Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unlocking the potential of PROTACs: A comprehensive review of protein degradation strategies in disease therapy.
    Bhole RP; Kute PR; Chikhale RV; Bonde CG; Pant A; Gurav SS
    Bioorg Chem; 2023 Oct; 139():106720. PubMed ID: 37480814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PROTAC targeted protein degraders: the past is prologue.
    Békés M; Langley DR; Crews CM
    Nat Rev Drug Discov; 2022 Mar; 21(3):181-200. PubMed ID: 35042991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential of the nanoplatform and PROTAC interface to achieve targeted protein degradation through the Ubiquitin-Proteasome system.
    Xie H; Zhang C
    Eur J Med Chem; 2024 Mar; 267():116168. PubMed ID: 38310686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PROTACs technology for treatment of Alzheimer's disease: Advances and perspectives.
    Inuzuka H; Liu J; Wei W; Rezaeian AH
    Acta Mater Med; 2022; 1(1):24-41. PubMed ID: 35237768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras.
    Madan J; Ahuja VK; Dua K; Samajdar S; Ramchandra M; Giri S
    BioDrugs; 2022 Sep; 36(5):609-623. PubMed ID: 36098871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in targeted protein degraders as potential therapeutic agents.
    Yang N; Kong B; Zhu Z; Huang F; Zhang L; Lu T; Chen Y; Zhang Y; Jiang Y
    Mol Divers; 2024 Feb; 28(1):309-333. PubMed ID: 36790583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies.
    Ciechanover A; Kwon YT
    Exp Mol Med; 2015 Mar; 47(3):e147. PubMed ID: 25766616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deubiquitinating enzymes (DUBs): decipher underlying basis of neurodegenerative diseases.
    Liu B; Ruan J; Chen M; Li Z; Manjengwa G; Schlüter D; Song W; Wang X
    Mol Psychiatry; 2022 Jan; 27(1):259-268. PubMed ID: 34285347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders.
    Diehl CJ; Ciulli A
    Chem Soc Rev; 2022 Oct; 51(19):8216-8257. PubMed ID: 35983982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PROTAC-DB 2.0: an updated database of PROTACs.
    Weng G; Cai X; Cao D; Du H; Shen C; Deng Y; He Q; Yang B; Li D; Hou T
    Nucleic Acids Res; 2023 Jan; 51(D1):D1367-D1372. PubMed ID: 36300631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.